Editas Medicine (EDIT) – Company Press Releases
-
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
-
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
-
Editas Medicine to Participate in Upcoming Investor Conferences
-
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
-
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
-
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
-
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
-
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
-
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
-
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
-
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
-
Editas Medicine Announces Upcoming Investor Events
-
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
-
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
-
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
-
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
-
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
-
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
-
Editas Medicine Announces Pricing of Offering of Common Stock
-
Editas Medicine Announces Offering of Common Stock
-
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
-
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
-
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
-
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
-
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
-
Editas Medicine Announces First Quarter 2023 Results and Business Updates
-
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
-
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
-
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
-
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
-
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
-
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
-
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
-
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
-
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
-
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
-
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
-
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
-
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
-
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
-
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
-
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
-
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
Back to EDIT Stock Lookup
